Scancell Holdings plc (SCNLF)
OTC
Healthcare
Biotechnology
$0.13
▼ -16.44%
Market Cap
$133.1M
Sector
Healthcare
Industry
Biotechnology
Beta
0.74
52-Wk Range
0.1191-0.33487
CEO
Phillip John L'Huillier
Country
GB
Currency
USD
Scancell Holdings plc is a biopharmaceutical company in the clinical development stage, focused on creating novel vaccines and antibody-based treatments. Its mission is to tackle significant unmet medical needs in both cancer and infectious diseases. The firm's developing therapies include SCIB1, an ImmunoBody cancer vaccine specifically for metastatic melanoma; the SCIB2/iSCIB2 vaccine, currently being evaluated for its effectiveness against various solid tumors, such as non-small cell lung cancer; and Modi-1, which is progressing through Phase I/II clinical trials for head and neck, triple-n…
Open full interactive analysis & DCF →